These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34021022)

  • 1. Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model.
    Shi Y; Xie TX; Leach DG; Wang B; Young S; Osman AA; Sikora AG; Ren X; Hartgerink JD; Myers JN; Rangel R
    Cancer Prev Res (Phila); 2021 Aug; 14(8):767-778. PubMed ID: 34021022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
    Wang J; Xie T; Wang B; William WN; Heymach JV; El-Naggar AK; Myers JN; Caulin C
    Cancer Prev Res (Phila); 2017 Dec; 10(12):684-693. PubMed ID: 29018057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
    Monteiro de Oliveira Novaes JA; Hirz T; Guijarro I; Nilsson M; Pisegna MA; Poteete A; Barsoumian HB; Fradette JJ; Chen LN; Gibbons DL; Tian X; Wang J; Myers JN; McArthur MJ; Bell D; William WN; Heymach JV
    Cancer Prev Res (Phila); 2021 Mar; 14(3):313-324. PubMed ID: 33277316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral-specific ablation of Klf4 disrupts epithelial terminal differentiation and increases premalignant lesions and carcinomas upon chemical carcinogenesis.
    Paparella ML; Abrigo M; Bal de Kier Joffe E; Raimondi AR
    J Oral Pathol Med; 2015 Nov; 44(10):801-9. PubMed ID: 25605610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.
    Tan MT; Wu JG; Callejas-Valera JL; Schwarz RA; Gillenwater AM; Richards-Kortum RR; Vigneswaran N
    Int J Exp Pathol; 2020 Feb; 101(1-2):45-54. PubMed ID: 32436348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 blockade prevents the progression of oral carcinogenesis.
    Dong Y; Wang Z; Mao F; Cai L; Dan H; Jiang L; Zeng X; Li T; Zhou Y; Chen Q
    Carcinogenesis; 2021 Jun; 42(6):891-902. PubMed ID: 33993220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IL-17alpha to promote anti-PD-1 therapy effect by screening the tumor immune microenvironment in a mouse oral carcinogenesis model.
    Wang S; Yu X; Li F; Fan H; Zhao E; Hu Z
    Cancer Biomark; 2021; 31(4):339-350. PubMed ID: 33896829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions.
    Carenzo A; Serafini MS; Roca E; Paderno A; Mattavelli D; Romani C; Saintigny P; Koljenović S; Licitra L; De Cecco L; Bossi P
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.
    De Costa AM; Justis DN; Schuyler CA; Young MR
    Int Immunopharmacol; 2012 Jul; 13(3):322-30. PubMed ID: 22609090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis.
    Hasina R; Martin LE; Kasza K; Jones CL; Jalil A; Lingen MW
    Cancer Prev Res (Phila); 2009 Apr; 2(4):385-93. PubMed ID: 19336725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis.
    Wen L; Lu H; Li Q; Li Q; Wen S; Wang D; Wang X; Fang J; Cui J; Cheng B; Wang Z
    J Exp Clin Cancer Res; 2019 Jul; 38(1):299. PubMed ID: 31291983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
    Levingston CA; Young MR
    Int J Cancer; 2017 Apr; 140(7):1609-1619. PubMed ID: 27914100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion.
    Cecilio HP; Valente VB; Pereira KM; Kayahara GM; Furuse C; Biasoli ÉR; Miyahara GI; Oliveira SHP; Bernabé DG
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):681-686. PubMed ID: 32980903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the oral glucocorticoid system during black raspberry mediated oral cancer chemoprevention.
    Nedungadi D; Ryan N; Anderson K; Lamenza FF; Jordanides PP; Swingler MJ; Rakotondraibe L; Riedl KM; Iwenofu H; Oghumu S
    Carcinogenesis; 2022 Feb; 43(1):28-39. PubMed ID: 34888650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer.
    Young MR
    J Immunother; 2008; 31(2):148-56. PubMed ID: 18481384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus inhibits oral carcinogenesis through cell cycle control.
    Li Y; Wang Y; Li J; Ling Z; Chen W; Zhang L; Hu Q; Wu T; Cheng B; Wang Y; Xia J
    Biomed Pharmacother; 2021 Jul; 139():111545. PubMed ID: 33873145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4NQO induced carcinogenesis: A mouse model for oral squamous cell carcinoma.
    Sagheer SH; Whitaker-Menezes D; Han JYS; Curry JM; Martinez-Outschoorn U; Philp NJ
    Methods Cell Biol; 2021; 163():93-111. PubMed ID: 33785171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    García-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
    Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.